Resolve Therapeutics Finished RSLV-132 Trial Enrollment
The Phase 2 study of RSLV-132 evaluates its ability to reduce immune-driven symptoms in Sjögren's patients.
Updated on Oct. 8, 2026 in Biotech
Live Poll
Do you believe new pharmaceutical research is effectively improving treatment options for chronic autoimmune diseases?
Resolve Therapeutics has completed enrollment for a Phase 2, randomized, double-blind study of its drug candidate RSLV-132. The research, which is currently in the trial phase, evaluates the drug in 110 women with moderate-to-severe Sjögren's disease.
Why it matters
The study aims to determine if clearing extracellular RNA can successfully mitigate the autoimmune symptoms characteristic of Sjögren's disease. This trial provides a critical assessment of a potential therapeutic mechanism for a condition currently lacking targeted treatments.
RSLV-132 is an RNase-Fc fusion protein designed with a three-week serum half-life. It functions by digesting extracellular RNA and RNA bound to autoantibodies to dampen innate immune system activation.
The players
Resolve Therapeutics
A biotechnology firm developing RNase-Fc fusion proteins to modulate the innate immune system.
The details
The drug works by targeting circulating RNA that acts as an inflammatory trigger in autoimmune conditions. By enzymatically breaking down these nucleic acids, the therapeutic aims to reduce the persistent activation of the innate immune system. The study measures the change in cardinal symptoms from baseline at Day 169 to quantify the therapeutic impact of this clearance mechanism.
Timeline
October 7, 2026: Resolve Therapeutics announced the completion of participant enrollment.
Day 169: Participants will undergo evaluation for the study's primary endpoint.
Q2 2027: Topline results for the study are expected to be released.
The Tech Race
This study is part of an ongoing effort to translate enzymatic RNA degradation into clinical interventions for systemic autoimmune diseases. It follows the established research trajectory of using Fc-fusion proteins to extend drug presence in the bloodstream.
As this is a clinical trial, the drug is not yet available to the public or clinical practice. Patients and providers should monitor for the release of topline efficacy data in 2027 to understand the potential for future treatment options.
The takeaway
The success of this trial depends on the correlation between RNA clearance and the mitigation of Sjögren's cardinal symptoms at Day 169. Stakeholders should track the release of topline data in Q2 2027 to evaluate if this fusion protein offers a scalable alternative to current immune suppressants.
What happens next
Topline study results are projected for release in the second quarter of 2027.
Further reading
For more on the current landscape of autoimmune research, visit the Biotech section.
More information
View the formal trial protocol and design on the ClinicalTrials.gov study registration.
Live Poll
Do you believe new pharmaceutical research is effectively improving treatment options for chronic autoimmune diseases?
